Posted by Michael Wonder on 03 Mar 2026
Health Canada Approves Ozempic (semaglutide injection) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes
2 March 2026 - Novo Nordisk announced today that Health Canada has approved Ozempic (semaglutide injection) to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease and/or chronic kidney disease.
Health Canada's new indication approval is based on results from the pooled analysis of SUSTAIN 6, PIONEER 6, FLOW and SOUL that demonstrated treatment with Ozempic reduced the risk of major adverse cardiovascular events compared to placebo, when used in addition to standard of care.
